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Aims: Previous results by our group showed that the in vitro uterus-relaxing potency of β2-adrenergic
receptor (β2-AR) agonists and uterine cAMP accumulation are enhanced in case of visceral inﬂammation. Our
aim was to study the effects of the non-selective phosphodiesterase (PDE) inhibitor theophylline and the
selective PDE4 inhibitor rolipram on the uteri of intact late-pregnant female rats (on days 20 and 22 of
pregnancy) and of pregnant rats treated with lipopolysaccharide (LPS) to evoke preterm labor (on day 20).
Main methods: The effects of theophylline and rolipram alone and of rolipram with terbutaline were
investigated in isolated organ system. Contractions were evoked with KCl. The forskolin- and terbutaline-
stimulated cAMP accumulations were determined by enzyme immunoassay, with or without rolipram.
Key ﬁndings: The maximum uterus-relaxing effects of theophylline and rolipram decreased signiﬁcantly
(pb0.05) with the progression of pregnancy in intact rats. The most pronounced effect of rolipram was
detected in rats challenged with LPS on day 20. Rolipram increased the in vitro effect of terbutaline both in
intact and in LPS-treated rats. In the presence of rolipram, the forskolin- and terbutaline-stimulated cAMP
accumulations were higher in LPS-treated than in intact rats.
Signiﬁcance: The previous ﬁndings led us to conclude that the combined administration of PDE4 inhibitors
with β2-agonists is of therapeutic value for the inhibition for uterine contractions, especially in the case of
genital inﬂammation, which often triggers preterm birth. Combination therapy in general is associated with
lesser side-effects, as a consequence of lower effective doses of each drug.
© 2010 Elsevier Inc. All rights reserved.Introduction
Preterm uterine contractions can develop as a result of several
pathological processes, among which intrauterine infection plays a
key role (Romero et al., 1988). The inﬂammatory processes trigger a
wide range of uterus-contracting factors, which eventually lead to the
development of uterine contractions (Lindström and Bennett, 2005).
At the same time, the contractions in the pregnant myometrium are
counterbalanced in part by cyclic adenosine-monophosphate
(cAMP)-dependent relaxation mechanisms. A plethora of ligands
such as β2-adrenergic receptor (β2-AR) agonists can stimulate the
generation of cAMP in the myometrium, whereas phosphodiesterase
enzymes (PDEs) warrant termination of signalling by the degradation
of cAMP to the inactive 5′-AMP (Houslay 2003).
We earlier demonstrated that the in vitro uterus-relaxing potency
of the β2-AR agonist terbutaline is enhanced in pregnant rats
challenged with bacterial lipopolysaccharide (LPS) to evoke preterm
birth. We also found that, in case of local inﬂammation, terbutaline
has an increased cAMP-accumulating potency, which is probablyár).
l rights reserved.mediated by the sensitization of adenylyl cyclase by tumor necrosis
factor-α (TNF-α) (Klukovits et al., 2009). On the other hand, the local
PDE activity may as well be an important regulator of cAMP-
dependent relaxation processes.
The PDE enzymes are encoded by 11 related gene families and are
differentially expressed in human tissues (Lugnier, 2006). Human
myometrial cells (Méhats et al., 1999), amniochorionic membranes
(Oger et al., 2005), monocytes and neutrophils (Wang et al., 1999)
express PDE4, which promotes its role in either smooth muscle or
immune functions. At present, PDE4 comprises the largest PDE family,
constituted by 4 genes with various alternative mRNA splices
encoding at least 35 different PDE4 isoenzymes. Rolipram is the
archetypal PDE4 inhibitor (Ki=0.8 μM); and no selective inhibitor is
currently available that discriminates PDE4 isoenzymes (Lugnier,
2006).
The aim of the present studywas to test the effects of non-selective
PDE or selective PDE4 inhibitors alone or in combination with β2-AR
agonists on uterine contractions in vitro. We tested the effects of the
non-selective PDE inhibitor theophylline and the speciﬁc PDE4
inhibitor rolipram on isolated uterine rings from intact and LPS-
treated late-pregnant rats. We also investigated the effects of β2-AR
agonist terbutaline with PDE4 blockade in the same experimental
model. Uterine cAMP levels were measured by means of enzyme
































Fig. 1. Effects of theophylline on pregnant uterine contractions in vitro. The
contractions were elicited with 25 mM KCl in uterine rings of intact rats on days 20
(■) and 22 (♦) of pregnancy, and in LPS-treated rats on day 20 (●) of pregnancy. n=8
in each group.
734 A. Klukovits et al. / Life Sciences 87 (2010) 733–737immunoassay (EIA) after stimulation with the direct adenylyl cyclase
activator forskolin, in the presence of rolipram. The accumulation of
cAMP was also detected in the presence of terbutaline and rolipram
alone, and their combination.
Methods
Animals
The animals were treated in accordance with the European
Communities Council Directives (86/609/ECC) and the Hungarian
Act for the Protection of Animals in Research (XXVIII.tv.32.§). All
experiments involving animal subjects were carried out with the
approval of the Hungarian Ethical Committee for Animal Research
(registration number: IV./01758-2/2008) and under the control of the
ISO-9001:2008 Quality Management System.
Sexuallymature female Sprague–Dawley rats (bodymass: 140-160 g,
50–60 days old) weremated in the earlymorning hours. Copulationwas
conﬁrmed by the presence of a copulation plug or spermatozoa in the
vagina. The day of copulation was considered to be the ﬁrst day of
pregnancy. The animals were housed in temperature- (20–23 °C),
humidity- (40–60%) and light- (12 h of light, 12 h of dark) regulated
rooms, with water and food intake ad libitum.
In vivo treatments
The animals were divided into 3 groups (n=6–8 in each): (1)
intact pregnant rats on day 22 of pregnancy; (2) intact pregnant rats
on day 20 of pregnancy; and (3) rats treatedwith LPS (i.p. 125 μg/day)
in the early morning hours for three consecutive days from day 18 of
pregnancy to evoke preterm birth, which occurred during the early
afternoon of day 20 (Elovitz and Mrinalini, 2004).
In vitro contractility studies
Ondays 20 and 22 of pregnancy the ratswere killed by CO2 inhalation
in the early afternoon hours, and the uteri were removed and prepared
for the in vitro contractility assay, as itwas reportedpreviously (Klukovits
et al. 2004). Brieﬂy, the isolated uterine horns were immediately placed
in an organ bath (de Jongh solution; containing inmM: 137NaCl, 3 KCl, 1
CaCl2, 1 MgCl2, 12 NaHCO3, 4 Na2HPO4, 6 glucose; pH 7.4) perfused with
95% oxygen and 5% carbon dioxide; they were trimmed of fat and the
foeto-placental units were removed. Temperature was maintained at
37 °C. Four rings 1 cm longwere sliced from themiddle part of eachhorn,
including implantation sites, and tested in parallel; they were mounted
vertically in the above-mentioned organ bath under the same conditions.
After mounting, the initial tension was set at 1.5 g and the rings were
equilibrated for 60 min, with change of the buffer every 15 min.
Rhythmic contractions were then elicited with 25 mM KCl. The effects
of the non-speciﬁc PDE inhibitor theophylline, the speciﬁc PDE4 inhibitor
rolipram and/or the β2-AR agonist terbutaline on uterine rings were
measured in the concentration range 10−12–10−5 M, in a cumulative
manner. The tissue samples were incubated for 4 min with each
concentration. The tension of the myometrial rings was measured with
a strain gauge transducer (SG-02, Experimetria Ltd, Budapest, Hungary),
and recorded and analysed with the SPEL Advanced ISOSYS Data
Acquisition System (Experimetria Ltd, Budapest, Hungary). Areas under
the curves (AUCs) of 4-min periods were evaluated; the effects of
rolipram and terbutaline were expressed as percentages of the KCl-
induced contractions preceding the administration of the relaxing drugs.
The maximum contraction-inhibiting values were calculated.
Measurement of uterine cAMP accumulation
Uterine samples from intact 22-day pregnant and LPS-treated 20-day
pregnant rats were incubated in de Jongh solution, under the sameconditions as detailed above. Forskolin (10−8–10−6 M) -stimulated
cAMP accumulationwas determined in the presence of the speciﬁc PDE4
inhibitor rolipram (10−8 or 10−5 M). The extents of cAMP accumulation
were also determined in the presence of terbutaline (10−7 M) or
rolipram (10−6 M) alone, and also in combination. After stimulation, the
samples were immediately frozen in liquid nitrogen and stored until the
extraction of cAMP (Gaspar et al., 2007). Frozen tissue sampleswere then
ground, weighed, homogenized in 10 volumes of ice-cold 5% trichlor-
oacetic acid and centrifuged at 1000 g for 10 min. The supernatants were
extracted with 3 volumes of water-saturated diethyl ether. After drying,
the extracts were stored at−70 °C until the cAMP assay. Uterine cAMP
accumulation was measured with a commercial competitive cAMP EIA
Kit, tissue cAMP levels were expressed in pmol/mg tissue.
Statistical analyses
All experiments were carried out on at least 6 animals and each
value is given as a mean±S.E.M. All the data calculations, curve
ﬁttings (sigmoidal concentration–response curves), and statistical
analyses were performed with the Prism 4.0 computer software
(Graph Pad Software Inc, San Diego, CA, USA). Group comparisons
were made by one-way ANOVA tests with Newman–Keuls post-test.
Drugs
Rolipram, theophylline, terbutaline, LPS (E. coli endotoxin 055:B5),
3-isobutyl-1-methylxanthine, forskolin and the cAMP EIA Kit were
purchased from Sigma-Aldrich Ltd, Budapest, Hungary.
Results
In vitro contractility studies
Uterine activity was characterized by the AUCs of KCl-stimulated
contractions of uterine rings in vitro. Time control experiments revealed
thatKCl-stimulated contractionsdonotdecrease signiﬁcantly through the
experiment (40–45 min). Although the non-speciﬁc PDE inhibitor
theophylline had very limited effect in the uteri of intact rats, it showed
signiﬁcant effect in LPS-treated rats (Fig. 1). In the intact rats, the effect of
theophylline varied, depending on the day of pregnancy: the KCl-induced
contractionswere reducedby theophylline to 47.04±3.53 S.E.M.%onday
20 (2 days before physiological term) and to 74.66±2.46 S.E.M.% on day
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Fig. 3. Effect of rolipram on the uterine-relaxing effect of terbutaline in vitro. The
contractions were elicited with 25 mM KCl in uterine rings of intact rats on day 22 (■)
(Fig. 3A) or of LPS-treated rats on day 20 (▼) of pregnancy (Fig. 3B). In the presence of
10−6 M rolipram, the maximum contraction-inhibiting effects of terbutaline were
lower both in the intact (pb0.05) and in the LPS-treated rats (pb0.01). n=8 in each
735A. Klukovits et al. / Life Sciences 87 (2010) 733–73722(atphysiological term)(pb0.001). In thegroupof rats treatedwithLPS,
which delivered on day 20, theophylline decreased the contractions to
54.89±10.90 S.E.M.%, whichwas not different from that in the intact rats
on day 20 (pN0.05) butwas lower than that onday 22 (pb0.05). The EC50
values of theophyllinewere not different (pN0.05) in the intact rats either
onday 20 (1.67±1.11×10−9 M) or onday 22 (4.20±1.81×10−8 M), or
in the LPS-treated rats (3.52±2.34×10−8 M).
The contraction-inhibiting effect of the speciﬁc PDE4 inhibitor
rolipram exhibited a similar tendency: a declining relaxing effect towards
term (Fig. 2). In the intact late-pregnant rats, the maximum contraction-
inhibiting effectwas seen on day 20,when the contractionswere reduced
to 54.85±4.21 S.E.M.%. The effect of rolipramwas theweakest on day 22,
when the contractions were reduced to 77.66±7.13 S.E.M.%, resulting in
aweaker (pb0.05) inhibition than that on day 20. In the LPS-treated rats,
however, the contractions were reduced to 19.1±4.96 S.E.M.%, resulting
in amoremarked inhibition than that in intact rats onday20 (pb0.01). As
regards the EC50 values of rolipram, despite the increasing trend in the
values towards physiological term, there were no signiﬁcant differences
(pN0.05) between the intact rats and the LPS-treated rats.
The effects of the β2-AR agonist terbutaline alone or in the presence
of rolipram were also tested on the isolated uterine rings. Terbutaline
decreased the KCl-stimulated contractions to 39.23%±4.14 S.E.M.%, on
day 22 of pregnancy (Fig. 3A). In the presence of 10−6 M rolipram, the
contractions were reduced by terbutaline to 25.98±2.98 S.E.M.%
(pb0.05). In the LPS-treated rats (Fig. 3B), on day 20 of pregnancy,
terbutaline alone decreased the uterine contractions to 35.75±3.60 S.E.
M.%, while in the presence of rolipram the KCl-induced contractions
were reduced to 9.85±5.21 S.E.M.% (pb0.01).
Uterine cAMP levels
The effects of the adenylyl cyclase activator forskolin were at ﬁrst
investigated in intact 22-day-pregnant and LPS-treated 20-day-pregnant
rats. In the presence of rolipram (10−8 M), forskolin (10−8–10−6 M)
concentration-dependently increased the uterine cAMP levels in both
groups (Fig. 4A). In the uteri of the LPS-treated rats, 10−8, 10−7 and
10−6 M forskolin all evoked higher cAMP accumulation than in intact 22-
day-pregnant rats (pb0.001). Similarly, when rolipram was present in
higher concentration (10−5 M) (Fig. 4B), 10−8, 10−7 and 10−6 M
forskolin stimulation again resulted in signiﬁcantly higher uterine cAMP
concentrations in the LPS-treated than in the intact rats (pb0.01). At 10−8

































Fig. 2. Effects of rolipram on pregnant uterine contractions in vitro. The contractions
were elicited with 25 mMKCl in uterine rings of intact rats on days 20 (■) and 22 (♦) of
pregnancy, and in LPS-treated rats on day 20 (●) of pregnancy. n=8 in each group.
group.higher in the presence of 10−5 M rolipram than of 10−8 M rolipram, in
both groups.
The cAMP generation in the pregnant uterus was measured in the
presence of terbutaline (10−7 M) or rolipram (10−6 M) alone and of
their combination (Fig. 5). Both in the intact and in the LPS-treated rats,
the cAMP concentrations were signiﬁcantly higher in the presence of
terbutaline+rolipram than with only terbutaline (pb0.001) or roli-
pram (pb0.001). The combination of terbutaline+rolipram resulted in
higher cAMP levels in the LPS-treated rats than in the intact rats
(pb0.01).
Discussion
Most of the interventions intended to reduce preterm birth rate
have not achieved consistent beneﬁt. Apart from manifest infections
in late-pregnancy, when the termination of pregnancy is of utmost
importance to save the mother and the infant, the causes of preterm
contractions are seldom recognized before the initiation of tocolytic
therapy. The administration of uterorelaxant drugs might provide
time for obstetrical interventions such as screening for asymptomatic




































Fig. 4. Intracellular cAMP levels in the pregnant rat uterus, in the presence of forskolin
and rolipram. In the presence of 10−8 M (Fig. 4A) or 10−5 M (Fig. 4B) rolipram,
forskolin (10−8–10−6 M) concentration-dependently increased the uterine cAMP
levels in intact rats on day 22 and in LPS-treated rats on day 20. In the uteri of the LPS-
treated rats, the extent of cAMP accumulation was higher than in those of the intact
rats. n=6 in each group; **: pb0.01; ***: pb0.001.
736 A. Klukovits et al. / Life Sciences 87 (2010) 733–737antibiotic treatment for group B streptococcal infections (Iams et al.,
2008; Withworth and Quenby, 2008). Early intervention, hospitali-
zation of the mother and the initiation of further treatment can

















Fig. 5. Intracellular cAMP levels in the pregnant rat uterus, in the presence of terbutaline
or rolipram and their combination. Both in the intact and in the LPS-treated rats, the
cAMP concentrations were higher in the presence of terbutaline+rolipram than with
only terbutaline (10−7 M; ***: pb0.001) or rolipram (10−6 M; ###: pb0.001). The
combination of terbutaline+rolipram resulted in higher cAMP levels in the LPS-treated
rats than in the intact rats (**: pb0.01). n=6 in each group.In view of the role of inﬂammation in the provocation of preterm
contractions, it appears advantageous to apply tocolytics with anti-
inﬂammatory effects. Both β2-AR agonists and PDE4 inhibitors were
reported to have an anti-inﬂammatory effect (Chi et al., 2004;
Hatzelmann and Schudt, 2001; Farmer and Pugin, 2000; Francischi
et al., 2000). In immunocompetent cells, where PDE4 enzymes are
abundant, increased cAMP levels lead to inhibition of the synthesis
and release of pro-inﬂammatory mediators, cytokines and active
oxygen species. The β2-AR agonists have immediate and comparable
profound effects on uterine activity (de Heus et al., 2008). Despite
their unfavorable side-effects (tachycardia and the risk of pulmonary
hypertension), the β2-AR agonists are still irreplaceable in tocolytic
therapy. Recent publications have recommended the use of PDE4
inhibitors for tocolysis, but clinical experience was controversial
(Méhats et al., 2007). Monotherapy with rolipram or roﬂumilast was
hindered by adverse effects such as unacceptable nausea and
vomiting (Dyke and Montana, 2002).
Our study conﬁrmed that the non-selective PDE inhibitor
theophylline has only limited uterorelaxant effect in the late-pregnant
rat. The selective PDE4 inhibitor rolipram, however, turned out to be
much more effective to inhibit the KCl-induced uterine contractions.
In the late-pregnant rat uterus the administration of 25 mMKCl elicits
rhythmic, sustainable uterine contractions, which do not decline over
an approximately 45 min period. In this model, we could assess the
effects of the PDE inhibitors and of terbutaline in a cumulative
manner. In the in vitro contractility assay we observed a gestation-
dependent slight decline in the effect of theophylline and rolipram,
which suggests that intracellular cAMP accumulation is less appre-
ciable towards the very end of pregnancy. In LPS-treated rats, the
maximum effect of theophylline was similar to that in intact 20-day
pregnant rats. Contrarily, the effect of rolipram was signiﬁcantly
greater in the LPS-treated rats. Since the inhibition of PDE4 does not
affect cAMP production, but maintains high cAMP concentration in
the myometrium cells, our results indicate that inﬂammation
probably promotes cAMP generation in the uterus. It corresponds to
our previous ﬁndings that inﬂammatory processes in the late-
pregnant rat uterus potentiate cAMP-related uterine relaxation via
elevation of local and systemic TNF-α concentration (Klukovits et al.,
2009).
To investigate the extent of cAMP production in the uterus we
used forskolin to stimulate the membrane bound adenylyl cyclase. By
means of forskolin we could detect intracellular cAMP levels without
directly stimulating any membrane receptors (e.g. β-adrenergic,
relaxin, prostaglandin E2, nociceptin, calcitonin gene-related peptide)
which are coupled with stimulatory G-proteins, thus we rather
measured the capacity of uterine smooth muscle cells to produce
cAMP. We found that in the presence of rolipram the forskolin-
stimulated cAMP accumulation was higher in the uteri of LPS-treated
rats than in those of intact rats. The sensitization of adenylyl cyclase in
inﬂammation was reported recently by our group (Klukovits et al.
2004), corresponding to earlier ﬁndings of Osawa et al. (2007).
At the same time, we should note that inﬂammation may also
decrease PDE4 activity in the myometrium, resulting in a slower
turnover of cAMP and alter cAMP-mediated relaxation responses. In a
recent study, however, no change has been observed in the PDE
activity or PDE4B2 expression in the uteri of LPS-challenged pregnant
mice (Schmitz et al., 2007). Here we intended to focus on the
uterorelaxant effects induced by the combined administration of the
β2-agonist terbutalinewith the PDE4 inhibitor rolipram, and also their
effect on cAMP accumulation.
The combination of two uterorelaxant drugs may be beneﬁcial to
enhance and/or sustain myometrial relaxation. Another advantage of
applying a drug combination is to administer lower doses of the
individual drugs, which helps to avoid or diminish receptor
desensitization. The PDE4-selective rolipram was more effective on
the uterus than the non-selective PDE inhibitor theophylline, which
737A. Klukovits et al. / Life Sciences 87 (2010) 733–737corresponds to earlier ﬁndings on PDE4 transfected cells (Wang et al.,
2002). Hence, we chose rolipram to test the possible potentiating
effect of PDE4 inhibition on terbutaline-induced uterine relaxation.
Rolipram potentiated the relaxing effect of terbutaline by 13% in the
intact rats, and by 25% in LPS-treated rats. The most pronounced
relaxation – 90% – was detected in the LPS-treated rats, further
justifying our hypothesis that cAMP-dependent mechanisms play a
major role in the uterus in case of inﬂammation. Rolipram
unequivocally enhanced the terbutaline-induced relaxation, by
interfering with the PDE-catalyzed conversion of the biologically
active cAMP to 5′-AMP.
We further conﬁrmed the outstanding uterorelaxant effect of the
combination of terbutaline with rolipram by measuring the tissue
cAMP levels. Terbutaline alone generated a relatively small concen-
tration of cAMP in both animal groups. We note here that measuring
tissue cAMP levels without a PDE inhibitor being present is against the
conventional method, since cAMP is a rapidly inactivated intracellular
signalling molecule. However, we considered that measuring cAMP
concentration without a PDE inhibitor is of importance here, to
compare the individual versus the combined effect of terbutaline and
rolipram on cAMP accumulation. Likewise, we detected a moderate
cAMP accumulation in the presence of rolipram alone, without any
receptorial stimulation. With the combination of terbutaline and
rolipram, however, uterine cAMP levels were much higher, and the
highest level was found in the LPS-treated rats.
Our observations are in concordance with previous ﬁnding that
restraining the breakdown of cAMP with PDE4 inhibitors might act to
potentiate the effects of β2-AR agonists in asthma or COPD, whichmay
in turn result in synergy for inﬂammatory outcome measures such as
exacerbations (Lipworth, 2005). Unfortunately, long-term adminis-
tration of β2-AR agonists often leads to reduced therapeutic response
due to drug-induced desensitization of β2-ARs, and their effectiveness
is also corrupted by physiological changes in late pregnancy (Gáspár
et al., 2005; Giembycz, 1996). It is desirable to test the efﬁcacy of the
above drug combination on a long run, before drawing a conclusion
related to clinical application. It seems, however, that in case of
inﬂammation, the late-pregnant myometrium reacts with a higher
sensitivity to cAMP-dependent relaxation mechanisms. The enhanced
responsiveness of the myometrium to β2-AR stimulation and PDE4
inhibition is probably the consequence of a pathological situation,
which might become beneﬁcial as regard to tocolytic therapy.
Conclusion
In the light of our results, we can conclude that the uterus-relaxing
effect of terbutalinewas increased notably in the presence of the PDE4
inhibitor rolipram. The combination of terbutaline+rolipram seems
favorable to promotemyometrium relaxation, especially in the case of
genital inﬂammation, which condition is liable to trigger preterm
birth.
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